Companies › Alebund Pharmaceuticals
2 active drug programs in 2 registered trials: 1 Phase 3, 1 Phase 1; Genitourinary, Metabolic and endocrine; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AP301 Iron-based phosphate binder | – | Phase 3 | Hyperphosphatemia | Jan 2027 |
| AP303 | – | Phase 1 | Diabetic Kidney Disease | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06666283 | AP303 | Phase 1 | Diabetic Kidney Disease | Metabolic and endocrine | Sep 2025 |
| NCT06933472 | AP301 | Phase 3 | Hyperphosphatemia | Genitourinary | Jan 2027 |
No annotated target.
–
The United Bio-Technology (Hengqin) Vifor Pharma Sparrow Pharmaceuticals Maze Therapeutics BrightGene Bio-Medical Technology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.